All Posts Tagged With: "MRK"
(BMY) Bristol-Myers Squibb Company Kicks Off 2012 Pharma Deals
The spate of acquisitions in the pharma industry continues in 2012 with Bristol-Myers Squibb Company (BMY) announcing the first major deal of the new year. Major merger and acquisition (M&A) deals have taken place in the pharma sector over the last couple of years. With most...
9Jan2012 | vitalstocks | 0 comments | Continued(JNJ) Pharma & Biotech Stock Review & Outlook – Industry Outlook
With 2011 coming to an end, the pharmaceutical industry continues to face challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant...
29Dec2011 | vitalstocks | 0 comments | Continued(XRT) Stock Market News for December 14, 2011 – Market News
Markets eroded initial gains on Tuesday after it emerged that the Federal Reserve had no new gifts to offer to the economy. The central bank also cautioned that the global financial scenario poses a serious threat for the domestic economy. Additionally, with the pre-holiday rush...
14Dec2011 | vitalstocks | 0 comments | Continued(EU) Emerging Markets: The Way Forward
According to Irish orator, philosopher, & politician Edmund Burke, change is the most powerful law of nature. The winds of change seem to be sweeping across the pharmaceutical industry as well. Until recently, most commercialization efforts were focused on the U.S. —...
7Dec2011 | vitalstocks | 0 comments | Continued(JNJ) Spotlight on Hepatitis-C Market
Is the hepatitis-C market the next Mecca for the pharma/biotech sector? It seems so if we go by the flurry of activity and heightened interest in this market in the past few quarters. The hepatitis-C virus (HCV) market seems to have caught the eye of several pharma/biotech companies...
7Dec2011 | vitalstocks | 0 comments | Continued(ALNY) Alnylam Pharmaceuticals Completes Trial Enrollment
Alnylam Pharmaceuticals Inc. (ALNY) recently announced it has completed enrollment in a mid-stage study of its pipeline candidate ALN-RSV01, an RNA interference technology (RNAi) therapeutic being studied for the treatment of respiratory syncytial virus (RSV) infection. The study...
2Dec2011 | vitalstocks | 0 comments | Continued(ALNY) Alnylam Pharmaceuticals Reveals ALNTTR01 Trial Data
Alnylam Pharmaceuticals Inc. (ALNY) recently presented data from an early stage study of its pipeline candidate ALN-TTR01 at a scientific conference in Japan. ALN-TTR01 is a systemically delivered RNA interference technology (RNAi) therapeutic that employs a first-generation...
28Nov2011 | vitalstocks | 0 comments | Continued(DNDN) Dendreon Loss Narrows
Dendreon Corporation (DNDN) reported third-quarter 2011 loss (including stock-based compensation expense but excluding other special items) of 67 cents per share, which was narrower than the Zacks Consensus Estimate of 70 cents due to a slightly better-than-expected performance...
6Nov2011 | vitalstocks | 0 comments | Continued(AMD) Company News for October 31, 2011 – Corporate Summary
• Advanced Micro Devices, Inc. (NYSE:AMD) posted third quarter earnings of $0.13 per share, ahead of the Zacks Consensus Estimate of $0.10 per share • Goodyear Tire & Rubber Co. (NYSE:GT) reported a profit of $161 million or $0.60 per share in the third quarter...
2Nov2011 | vitalstocks | 0 comments | Continued(PRGO) Perrigo Beats Earnings Forecast – Sales Miss
Perrigo Company (PRGO) reported earnings per share of $1.10 for the first quarter of fiscal 2012, beating the Zacks Consensus Estimate of $1.03 and the year-earlier earnings of 87 cents per share. Light sales performance was offset by a lower tax rate to drive earnings growth. First...
2Nov2011 | vitalstocks | 0 comments | Continued(AA) Stock Market News for October 12, 2011 – Market News
On Tuesday, markets ended mixed after trading in a tight range throughout the day, as investors anxiously waited for Slovakia’s vote for or against bolstering Europe’s financial rescue plan. Investors also eagerly awaitedAlcoa’s quarterly results, which would kick-start...
12Oct2011 | vitalstocks | 0 comments | Continued(ALNY) Alnylam Pharmaceuticals Announces Pipeline Progress
Recently, Alnylam Pharmaceuticals Inc. (ALNY) announced the commencement of an early-stage stage study (n~32) of its RNAi (RNA (Ribo Nucleic Acid) interference) therapeutic program ALN-PCS for treating patients suffering from hypercholesterolemia. Hypercholesterolemia indicates...
6Oct2011 | vitalstocks | 0 comments | Continued(ENZN) Enzon Pharmaceuticals Plans a 50% Workforce Cut
Enzon Pharmaceuticals (ENZN) recently announced that it will reduce its workforce by almost half to better align its resources with much tempered pipeline activities. The research and development pipeline at Enzon was reduced drastically in the last few months. During the second...
27Sep2011 | vitalstocks | 0 comments | Continued(EU) Pharmaceuticals Stock Outlook – September 2011 – Industry Outlook
The pharmaceutical industry continues to be impacted by major issues such as sluggish prescription trends, European Union (EU) pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to witness a significant imbalance...
23Sep2011 | vitalstocks | 0 comments | Continued(MRK) Merck Drug Candidate Presents New Data
Merck (MRK) recently presented new clinical and pre-clinical data on its phase III pipeline candidate, odanacatib. Odanacatib is an investigational cathepsin K (cat-K) inhibitor which is being developed for the treatment of osteoporosis in post-menopausal women. Results were...
21Sep2011 | vitalstocks | 0 comments | Continued(AZN) AstraZeneca Coverage Initiated at Neutral
We are initiating coverage on AstraZeneca (AZN) with a Neutral recommendation and a target price of $47.00. AstraZeneca, headquartered in London, UK, is one of the largest biopharmaceutical companies in the world. AstraZeneca’s business can be broken down into separate lines...
21Sep2011 | vitalstocks | 0 comments | Continued(BMY) Bristol-Myers Squibb Presents HCV Data
Recently, Bristol-Myers Squibb Company (BMY) presented encouraging data from a phase II study (n=48) which evaluated its candidate BMS-790052 in combination with peginterferon and ribavirin (standards of care) for treating patients suffering from the hepatitis C virus (HCV)....
20Sep2011 | vitalstocks | 0 comments | Continued(NVO) Novo Nordisk Data Presented at European Association for the Study of Diabetes
Novo Nordisk (NVO) recently presented data from two trials of its lead diabetes drug, Victoza, at the European Association for the Study of Diabetes (EASD). The first trial showed that using Victoza at an early stage in diabetes treatment of patients with type II diabetes, who...
19Sep2011 | vitalstocks | 0 comments | Continued(ENZN) Enzon Pharmaceuticals Analyst Downgrades Shares to Sell
We recently downgraded our rating on Enzon Pharmaceuticals Inc. (ENZN) from Neutral to Underperform with a target price of $9.50. In mid-May 2011, Enzon announced plans to halt the development of its lead pipeline compound PEG-SN38 (EZN-2208), a PEGylated version of the active...
15Sep2011 | vitalstocks | 0 comments | Continued(SCR) Simcere Drug Cleared in China
Recently, the State Food and Drug Administration (SFDA) of China delivered a boost to Simcere Pharmaceutical Group (SCR) by clearing its drug Iremod, for treating patients suffering from active rheumatoid arthritis (RA). Iremod, developed solely by Simcere, will be the first...
1Sep2011 | vitalstocks | 0 comments | Continued(ALNY) Alnylam Pharmaceuticals Analyst Maintains Neutral Rating on Shares
We have maintained a Neutral rating on Alnylam Pharmaceuticals, Inc (ALNY) with a target price of $7.00 per share. Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics based on a biological breakthrough technology known as RNA (Ribo Nucleic...
30Aug2011 | vitalstocks | 0 comments | Continued(GDP) Stock Market News for August 22, 2011 – Market News
Fears of a global downturn dragged the markets down on Friday and benchmarks registered their fourth consecutive week of losses. While recession worries in US unnerved investors, fears of financial destabilization on the European front strengthened the bearish mood. Posting its...
22Aug2011 | vitalstocks | 0 comments | Continued(GILD) Take Advantage of the Fire Sale in Healthcare
by Marc Lichtenfeld, Investment U Senior Analyst Wednesday, August 17, 2011: Issue #1580 The market’s violent sell-off over the past two weeks took down many good stocks along with the bad ones. Even with the quick bounce, quality companies are still trading at steep discounts...
18Aug2011 | InvestmentU | 0 comments | Continued(SCR) Simcere Pharmaceutical Group Beats on Bottom Line
Simcere Pharmaceutical Group’s (SCR) second quarter 2011 earnings of 21 cents per American Depositary Share (ADS) surpassed the Zacks Consensus Estimate of 13 cents and the year-ago earnings of 10 cents. Increased revenues and lower share count helped boost earnings. Revenues Revenues...
16Aug2011 | vitalstocks | 0 comments | Continued(ENZN) Enzon Pharmaceuticals’ Weak Top Line Widens Loss
Enzon Pharmaceuticals’ (ENZN) second quarter 2011 net loss of 12 cents per share (excluding restructuring charge) was wider than the loss of 8 cents suffered in the year-ago quarter as the decline in royalty revenue neutralized the savings from cost-cutting initiatives. The...
9Aug2011 | vitalstocks | 0 comments | Continued(XLF) Stock Market News for August 9, 2011 – Market News
Standard & Poor’s downgraded the US credit rating by a notch, delivering a crushing blow to benchmarks on Monday. Tension from the other side of the Atlantic also dampened sentiment as Europe was gripped by debt woes. Investors also struggled to find a clear answer about...
9Aug2011 | vitalstocks | 0 comments | Continued(AMGN) Company News for August 1, 2011 – Corporate Summary
• Chevron Corp. (NYSE:CVX) reported a jump in its second-quarter 2011 profits, benefiting from higher oil prices and stronger refining margins. Earnings per share (excluding adjustments for foreign-currency effects) came in at $3.89, beating the Zacks Consensus Estimate...
1Aug2011 | vitalstocks | 0 comments | Continued(AMGN) Debt Ceiling Debate and Dismal GDP Add To Market Stress
The debt debate continues to steal the spotlight from earnings and economic reports. The stock market has lost ground in recent days due to this uncertain environment even as corporate earnings reports have broadly come ahead of expectations. With both sides in the debt debate...
31Jul2011 | vitalstocks | 0 comments | Continued(AMGN) Amgen Beats Earnings Expectations – Updates Outlook
Amgen (AMGN) reported second quarter earnings per share of $1.35, 5 cents above the Zacks Consensus Estimate and 0.7% above the year-ago earnings. Total revenues increased 4% to $3,959 million in the second quarter of 2011. Revenues topped the Zacks Consensus Estimate of $3,778...
30Jul2011 | vitalstocks | 0 comments | Continued(XLF) Stock Market News for July 19, 2011 – Market News
Lingering euro-zone debt worries and the impasse over debt-ceiling negotiations weighed down investor sentiment on Monday, while bank shares felt the burn of the markets’ downtrend. The Dow Jones Industrial Average (DJIA) shed 0.8% to close at 12,385.16. The Standard &...
19Jul2011 | vitalstocks | 0 comments | Continued